Leading personalized medicine providers, Massive Bio and Health in Code, announced today a groundbreaking collaboration. This partnership is set to redefine the landscape of cancer treatment by combining Massive Bio’s Artificial Intelligence (AI) capabilities with Health in Code’s advanced genomic testing. 
 
The collaboration focuses on delivering personalized medicine to cancer patients, which is essential in the present era where precision oncology is becoming paramount. By incorporating biomarker testing and genomic data into clinical decision-making, both organizations aim to provide more accurate and individualized treatments for cancer patients. 
 
The core of the collaboration lies in the goal to increase patient access to clinical trials and precision oncology. Integrating Health in Code’s state-of-the-art cancer genetic knowledge and testing capabilities with Massive Bio’s AI-driven prescreening tools are expected to improve health outcomes and significantly reduce costs. This union is promising, especially for patients in Spain, where Health in Code has a significant presence. 
 
“By harnessing the power of AI and cutting-edge genomic testing, we’re stepping into a new frontier of oncology treatment. This collaboration is a testament to our commitment to offering cancer patients the most appropriate clinical trials analysis possible, tailored to their unique genetic makeup” said Toygun Onaran, CFO of Massive Bio. 
 
The partnership between Massive Bio and Health in Code is not merely transactional but it is built on shared values and a commitment to groundbreaking research. Both organizations believe that this collaboration will set a new standard in cancer care, emphasizing a data-driven and patient-centric approach. They are planning a series of webinars and patient engagement events in the upcoming months to educate the public about the benefits of biomarker detection for personalized medicine and the breakthroughs this collaboration aims to achieve. This commitment to patient education and advocacy further underscores their collective dedication to transforming the future of oncology. 
 
“Health in Code Group has always focused its efforts on making available to clinicians state-of-the-art technology and all the knowledge necessary for the implementation of genetic biomarkers in cancer patients management. By collaborating with Massive Bio, we will facilitate oncology patients access to clinical trials, enabling them to benefit from precision medicine”, remarked Inés Calabria, PhD, Head of Oncology at Health in Code.